Results from the EXCEL QOL study reported at TCT 2017 and published simultaneously in JACC

October 30, 2017

DENVER - October 30, 2017 - New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left main coronary artery disease (LMCAD) receiving percutaneous coronary intervention (PCI) versus coronary artery bypass graft surgery (CABG) found significant and similar QoL improvement at three years, although a greater benefit was observed with PCI at one month.

Findings were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in the Journal of the American College of Cardiology.

The EXCEL trial randomized patients with LMCAD of low to intermediate complexity to undergo revascularization by PCI with a second generation everolimus-eluting stent or CABG. Presented at TCT 2016 and published in the New England Journal of Medicine, rates of death, stroke, and myocardial infarction were similar with both PCI and CABG at a median of three years. However, the timing of clinical events and rates of repeat revascularization differed between the two groups.

Of the 1,905 patients with LMCAD who were randomized to undergo CABG or PCI in the EXCEL trial, 1,788 participated in the QoL sub-study. QoL was assessed at baseline and one, 12, and 36 months using the Seattle Angina Questionnaire, the SF-12, the Rose Dyspnea Scale, the Patient Health Questionnaire-8, and the EQ-5D. Differences between PCI and CABG were assessed using longitudinal random-effect growth curve models.

In the PCI group, both disease specific and generic health status measures improved significantly by one month, and these improvements were largely sustained at 12 and 36 months. In contrast, patients assigned to CABG demonstrated only small improvements or even declines in health status on several scales (especially measures of physical limitation) at one month. However, by 12 and 36 months, health status had improved significantly across all scales in the CABG group to levels commensurate with the PCI group. In contrast to previous studies of PCI vs. CABG, there was no evidence of preferential benefit of CABG in any patient subgroups.

"Among patients with LMCAD with low or intermediate coronary artery disease complexity, PCI using a second generation everolimus-eluting stent and CABG result in substantial and similar quality of life improvement through 36 months, with a greater early benefit observed with PCI," said Suzanne J. Baron, MD with Saint Luke's Mid America Heart Institute in Kansas City, MO. "Taken together with the three-year clinical data from EXCEL, these results suggest that PCI and CABG provide comparable intermediate-term outcomes for appropriately selected patients. Further studies are needed to evaluate the durability of health status benefits with PCI compared to CABG beyond three years in patients with LMCAD."
-end-
The EXCEL QOL trial was funded by a research grant from Abbott Vascular. Dr. Baron reported receiving consulting fees from Edwards Lifesciences and St. Jude Medical Inc., as well as travel reimbursement from Medtronic.

Cardiovascular Research Foundation

Related Health Status Articles from Brightsurf:

Psychological status rather than cognitive status is associated with incorrect perception of risk of falling in patients with moderate stage dementia
Dementia is associated with an impaired self-perception with potentially harmful consequences for health status and clinical risk classification in this patient group with an extraordinary high risk of falling.

Effect of hydroxychloroquine on clinical status
This randomized trial compares the effects of hydroxychloroquine versus placebo on patients' clinical status at 14 days (home, requiring noninvasive or invasive ventilation or extracorporeal membrane oxygenation, hospitalized, died) among adults hospitalized with COVID-19.

An app monitors cancer patients' health status and rewards participation
Gamification is becoming increasingly common in educational settings, but can also be used in other fields such as health.

Higher economic status does not always translate to better heart health
Upward income mobility is associated with a trade-off between well-being and cardiometabolic health.

The status of women
What drives people seek to high social status? A common evolutionary explanation suggests men do so because, in the past, they were able to leverage their social position into producing more children and propagating their genes.

Study links Medicaid expansion and recipients' health status
In Southern states that expanded their Medicaid programs under the Affordable Care Act, adults experienced lower rates of decline in both physical and mental health, according to research published this month in the journal Health Affairs.

How does fathers' physical and mental health status impact their children?
A new study has shown that children of fathers with poor mental health had a 2.6 times greater risk of having poor mental health.

How status sticks to genes
Life at the bottom of the social ladder may have long-term health effects that even upward mobility can't undo, according to new research in monkeys.

Artificial intelligence could use EKG data to measure patient's overall health status
Researchers applying artificial intelligence to electrocardiogram data estimated the age group of a patient and predicted their gender.

Cooperation with high status individuals may increase one's own status
While other animals tend to gain status through aggression, humans are typically averse to allowing such dominant individuals to achieve high status.

Read More: Health Status News and Health Status Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.